Last Close
May 15  •  04:00PM ET
21.97
Dollar change
-0.89
Percentage change
-3.89
%
Index
RUT
P/E
3.65
EPS (ttm)
6.01
Insider Own
1.24%
Shs Outstand
73.81M
Perf Week
-4.02%
Market Cap
1.62B
Forward P/E
9.46
EPS next Y
2.32
Insider Trans
0.00%
Shs Float
72.90M
Perf Month
-6.91%
Enterprise Value
1.34B
PEG
-
EPS next Q
0.42
Inst Own
102.92%
Perf Quarter
-3.22%
Income
504.34M
P/S
3.73
EPS this Y
-4.79%
Inst Trans
0.50%
Perf Half Y
-1.39%
Sales
434.49M
P/B
1.21
EPS next Y
-26.10%
ROA
32.63%
Perf YTD
9.90%
Book/sh
18.18
P/C
2.65
EPS next 5Y
-13.17%
ROE
50.72%
52W High
25.15 -12.63%
Perf Year
19.86%
Cash/sh
8.29
P/FCF
8.91
EPS past 3/5Y
- 10.35%
ROIC
30.24%
52W Low
16.52 32.99%
Perf 3Y
70.18%
EV/EBITDA
6.68
Sales past 3/5Y
325.77% 3.93%
Gross Margin
71.36%
Volatility
4.03% 3.00%
Perf 5Y
70.71%
EV/Sales
3.09
EPS Y/Y TTM
836.84%
Oper. Margin
36.93%
ATR (14)
0.72
Perf 10Y
105.33%
Quick Ratio
20.07
Sales Y/Y TTM
13.25%
Profit Margin
116.08%
RSI (14)
37.31
Current Ratio
21.13
EPS Q/Q
398.24%
SMA20
-4.76%
Beta
0.38
Debt/Eq
0.25
Sales Q/Q
10.17%
SMA50
-4.19%
Rel Volume
1.41
Prev Close
22.86
Employees
159
LT Debt/Eq
0.24
SMA200
5.80%
Avg Volume
708.36K
Price
21.97
IPO
Oct 05, 2004
Option/Short
Yes / Yes
Trades
Volume
996,537
Change
-3.89%
Date Action Analyst Rating Change Price Target Change
Feb-17-26Initiated BTIG Research Buy $35
Sep-30-25Initiated Goldman Sell $17
Aug-11-25Initiated Oppenheimer Outperform $45
Jul-14-25Initiated H.C. Wainwright Buy $40
Jul-11-25Initiated Cantor Fitzgerald Overweight $26
Mar-07-25Initiated Scotiabank Sector Outperform $55
Jun-18-24Initiated Cantor Fitzgerald Overweight
Jul-20-22Initiated Goldman Neutral $16
Nov-20-17Initiated Deutsche Bank Hold $13
May-06-26 05:43PM
04:05PM
Mar-01-26 04:27AM
Feb-28-26 08:26AM
06:45AM
01:48PM Loading…
Feb-26-26 01:48PM
Feb-25-26 08:17PM
05:08PM
04:05PM
Feb-24-26 01:14PM
01:02PM
Feb-19-26 08:21AM
08:00AM
Feb-18-26 09:17AM
Feb-04-26 07:55AM
08:23AM Loading…
Jan-08-26 08:23AM
Dec-21-25 09:57AM
Dec-12-25 04:56PM
Dec-11-25 06:35PM
Nov-25-25 07:00AM
Nov-14-25 04:47AM
Nov-05-25 06:40PM
05:33PM
04:05PM
Nov-04-25 08:00AM
Oct-31-25 09:00AM
Oct-30-25 07:55AM
Oct-23-25 05:02AM
Oct-21-25 08:00AM
Oct-20-25 08:00AM
07:30AM Loading…
Oct-14-25 07:30AM
Oct-10-25 06:21AM
Oct-07-25 09:40AM
08:00AM
Sep-17-25 02:27PM
Aug-26-25 07:00AM
Aug-13-25 08:00AM
Aug-12-25 04:05PM
Aug-11-25 09:33AM
Aug-06-25 05:06PM
04:05PM
Jun-12-25 07:00AM
Jun-10-25 06:00AM
Jun-03-25 07:00AM
May-20-25 06:00AM
May-08-25 08:54AM
May-07-25 05:52PM
04:05PM
Apr-11-25 12:30AM
Mar-21-25 06:35PM
Mar-14-25 06:17PM
Mar-12-25 05:08PM
Mar-05-25 07:00AM
Feb-26-25 04:35PM
04:04PM
Feb-06-25 07:00AM
Dec-17-24 07:25AM
Dec-16-24 07:00AM
01:15AM
Nov-26-24 07:00AM
Nov-21-24 11:14PM
Nov-12-24 04:05PM
Nov-06-24 05:23PM
04:05PM
Sep-04-24 07:00AM
Jul-31-24 10:54PM
05:51PM
04:05PM
Jul-09-24 01:30PM
Jun-27-24 08:00AM
Jun-18-24 09:51AM
Jun-03-24 07:00AM
May-31-24 07:30AM
May-20-24 04:06AM
May-10-24 02:04PM
May-08-24 10:57PM
05:09PM
04:05PM
07:00AM
Apr-24-24 07:00AM
Mar-04-24 04:01PM
Feb-29-24 04:56PM
04:37PM
04:05PM
Feb-14-24 02:44AM
Jan-10-24 06:16PM
Nov-18-23 07:03AM
Nov-03-23 06:00AM
Nov-01-23 05:32PM
04:15PM
04:05PM
Sep-19-23 08:30AM
Sep-18-23 08:00AM
Aug-25-23 04:52PM
Aug-02-23 05:18PM
04:05PM
Jul-23-23 09:22AM
Jul-11-23 08:53PM
08:00AM
Jul-06-23 11:33AM
Innoviva, Inc. engages in the development, commercialization, and financial management of biopharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate, and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Burlingame, CA.
CEO & DirectorMr. Pavel Raifeld C.F.A.
Chief Financial OfficerMr. Stephen Basso M.B.A.
Chief Accounting Officer & SecretaryMs. Marianne Zhen CPA
Chief Commercial Officer-Innoviva Specialty TherapeuticsMs. Patricia M. Drake
MPADr. David Altarac M.D.